16 April 2021 : Original article
Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial
Arman Faravardeh1DE*, Sanjeev Akkina2DE, Rafael Villicana3DE, Giselle Guerra4DE, Misbah A. Moten5ADE, Ulf Meier-Kriesche5ADE, Daniel R. Stevens5ACDE, Samir J. Patel5DE, Suphamai Bunnapradist6DEDOI: 10.12659/AOT.929535
Ann Transplant 2021; 26:e929535
Table 3 Fisher’s exact test was performed to compare the proportion of patients who either did or did not experience the adverse event.
| Event, n (%) | Switched to LCPT | Remained on IR-Tac |
|---|---|---|
| N=26 | N=29 | |
| Urinary tract infection | 1 (4) | 2 (7) |
| Diarrhea | 1 (4) | 1 (3) |
| Blood creatinine increased | 1 (4) | 1 (3) |
| Anemia | 1 (4) | 0 |
| Drug level increased | 1 (4) | 0 |
| Dyspepsia | 1 (4) | 0 |
| Hyperkalemia | 1 (4) | 0 |
| Leukopenia | 1 (4) | 0 |
| Nausea | 1 (4) | 0 |
| Nephropathy toxic | 1 (4) | 0 |
| Oral candidiasis | 0 | 1 (3) |
| Renal function test abnormal | 1 (4) | 0 |
| Urosepsis | 0 | 1 (3) |
| Vomiting | 1 (4) | 0 |
| IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus. | ||